How much revenue does Jiangxi Sanxin Medtec make?

Jiangxi Sanxin Medtec reported 1.64 billion CNY in revenue for fiscal year 2025, up 9.3% from 1.50 billion CNY in fiscal year 2024. In Q1 2026 revenue was 408.87 million CNY.

What is Jiangxi Sanxin Medtec's largest business segment?

Medical Device Industry, with 1.63 billion CNY or 100% of segment revenue in fiscal year 2025. Next: Other Business (under 1%).

Where does Jiangxi Sanxin Medtec make most of its revenue?

China: 78% of revenue by region in fiscal year 2025, followed by Foreign (22%).

What companies are similar to Jiangxi Sanxin Medtec?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS), Mingyue Optical Lens Co.,Ltd. (301101.SZ), BMC Medical Co., Ltd. (301367.SZ), Hangzhou AGS MedTech Co., Ltd. (688581.SS).

Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ) Stock

About Jiangxi Sanxin Medtec Co.,Ltd.

Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. It offers infusion and cardiothoracic surgery products and blood purification products, such as central concentrate delivery systems, disposable biological protein glue dispensers, disposable blood dialyzers, hemodialysis filters, hemodialysis concentrates and powders, continu...

At a glance

Jiangxi Sanxin Medtec reported revenue of 1.64 billion CNY for fiscal year 2025, up 9.3% from fiscal year 2024, and net income of 264.94 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 408.87 million CNY, up 13.4% from a year before. Its largest business segment, Medical Device Industry, brought in 100% of segment revenue in fiscal year 2025; China was the largest region with 78%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.